Chlordecone: development of a physiologically based pharmacokinetic tool to support human health risks assessments
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0738
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Chlordecone: development of a physiologically based pharmacokinetic tool to support human health risks assessments ; volume:96 ; number:4 ; day:5 ; month:2 ; year:2022 ; pages:1009-1019 ; date:4.2022
Archives of toxicology ; 96, Heft 4 (5.2.2022), 1009-1019, 4.2022
- Creator
-
Emond, Claude
Multigner, Luc
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00204-022-03231-3
- URN
-
urn:nbn:de:101:1-2022060719001202107614
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Emond, Claude
- Multigner, Luc
- SpringerLink (Online service)
Other Objects (12)
Interspecies extrapolation by physiologically based pharmacokinetic modeling
Human physiologically based pharmacokinetic model for propofol
Physiologically based pharmacokinetic modelling in health and disease for the support of pharmacotherapy
Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations
Translational physiologically-based pharmacokinetic (PBPK) modeling and simulation to support drug development and pharmacotherapy
Adapting physiologically-based pharmacokinetic models for machine learning applications
Highlight report: Interspecies extrapolation by physiologically based pharmacokinetic modeling
Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances
Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
Physiologically based pharmacokinetic modeling of arterial – antecubital vein concentration difference
A minimal physiologically based pharmacokinetic model for high-dose methotrexate
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Interspecies extrapolation by physiologically based pharmacokinetic modeling
Human physiologically based pharmacokinetic model for propofol
Physiologically based pharmacokinetic modelling in health and disease for the support of pharmacotherapy
Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations
Translational physiologically-based pharmacokinetic (PBPK) modeling and simulation to support drug development and pharmacotherapy
Adapting physiologically-based pharmacokinetic models for machine learning applications
Highlight report: Interspecies extrapolation by physiologically based pharmacokinetic modeling
Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances
Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
Physiologically based pharmacokinetic modeling of arterial – antecubital vein concentration difference
A minimal physiologically based pharmacokinetic model for high-dose methotrexate
Physiologically-based pharmacokinetic modelling for the prediction of adverse drug reactions
Interspecies extrapolation by physiologically based pharmacokinetic modeling
Human physiologically based pharmacokinetic model for propofol
Physiologically based pharmacokinetic modelling in health and disease for the support of pharmacotherapy
Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations
Translational physiologically-based pharmacokinetic (PBPK) modeling and simulation to support drug development and pharmacotherapy
Adapting physiologically-based pharmacokinetic models for machine learning applications
Highlight report: Interspecies extrapolation by physiologically based pharmacokinetic modeling
Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances
Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
Physiologically based pharmacokinetic modeling of arterial – antecubital vein concentration difference
A minimal physiologically based pharmacokinetic model for high-dose methotrexate